Some statistics place the number of cases of type 2 diabetes at 14% worldwide. This disease state is associated with numerous complications, including loss of vision, kidney failure, cardiovascular disease, and an increased rate of mortality. Current guidelines encourage early intervention with newer treatment options, including sodium-glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonist (GLP-1RA) medications. Given the shifting approaches to type 2 diabetes management, Deborah J. Wexler, MD, MSc, and colleagues developed a review of the literature addressing this topic.
Initially, 2,016 articles were identified for examination, and after applying the exclusion criteria, the review included 126 articles. Of these articles, 47 were randomized clinical trials, 22 were observational studies, 21 were categorized as systematic reviews and/or meta-analyses, 21 were guidelines developed, and 12 were narrative reviews. Additionally, three pharmaceutical or device reference guides were included.
The results of this review were published in JAMA. Dr. Wexler spoke with Physician’s Weekly (PW) about the findings of this examination and their applicability to practice.
